CLAIMS

1. Use of a fast dissolving wafer solid dosage form with a matrix for release of a biologically active material in an oral cavity in the manufacture of a medicament for treating depression, wherein said dosage form comprises:

(a) a biologically active material;

(b) a matrix forming agent;

wherein the dosage form dissolves in the oral cavity without leaving a residue of said

dosage form in the oral cavity that is detectable by a subject, thereby avoiding the urge for the subject to swallow the dosage form; and

wherein said dosage form disintegrates in the oral cavity in a time of less than 15 seconds and dissolves in the oral cavity in a time of less than 60 seconds.

2. The use of claim 1, wherein the solid dosage form is delivered sublingually.

3. The use according to anyone of the above claims, wherein the wafer is freeze-dried.

4. The use according to anyone of the above claims, wherein the solid dosage form is fast disintegrating.

5. The use according to anyone of the above claims, wherein the biologuically active material is absorbed by diffusion directly into the systemic circulation.

6. The use according to anyone of the above claims, wherein the biologically active material is selected from the group consisting of: ketamine, an analog, variant, metabolite and a salt form thereof.

7. The use according to anyone of the above claims, wherein the ketamine is present in an amorphous (non-crystalline) state.

8. The use according to anyone of the above claims, wherein the matrix forming agent comprises amylopectin.

9. The use according to anyone of the above claims, wherein the amylopectin is not in the form of a starch or modified starch.

10. The use according to anyone of the above claims, wherein the matrix forming agent comprises a carbohydrate.

11. The use according to anyone of the above claims, wherein the powder x-ray diffraction (XRD) spectrum of the dosage form comprises peaks at 2-theta values at approximately 9.58 degrees, 19.68 degrees, and 20.05 degrees.

12. The use according to anyone of the above claims, wherein the solid dosage form is porous.

13. The use according to anyone of the above claims, wherein the depression is selected from the group consisting of: major depressive disorder or treatment-resistant depression.

14. The use according to anyone of the above claims, wherein the solid dosage form comprises a dose of ketamine selected from the group consisting of: 25mg, 50mg, 75mg, 100mg, 150mg.

15. The use according to anyone of the above claims, wherein the solid dosage form provides an effective plasma concentration of ketamine material within a period of no more than two hours, 30 minutes, 20 minutes, or 15 minutes.

16. The use according to anyone of the above claims, wherein the solid dosage form provides a C_{max} at a comparable time to an IV injection but lower than that of an injection of the same dosage.

17. The use according to anyone of the above claims, wherein the solid dosage form provides a t_{max} at a comparable time to an IV injection.

18. The use according to anyone of the above claims, wherein the ketamine is rapidly absorbed with detectable concentrations at the first sampling time of 3 minutes.

19. The use according to anyone of the above claims, wherein the dosage form is to be administered to the subject utilising a dosing regimen selected from the group consisting of: at a frequency to alleviate the symptoms of depression, twice hourly, once every six hours, once every 12 hours, once daily, twice weekly, once weekly, once every two weeks, once a month, every two months, once every six months, once yearly.